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Abstract 
 
Background: Circulating cell-free DNA methylation testing in blood has recently 
received regulatory approval for screening of colorectal cancer. Its application in 
other clinical settings, including staging, prognosis, prediction, and recurrence 
monitoring is highly promising, and of particular interest in head and neck squamous 
cell carcinomas (HNSCC) that represent a heterogeneous group of cancers with 
unsatisfactory treatment guidelines.  
Methods: SHOX2 and SEPT9 DNA methylation in plasma from 649 prospectively 
enrolled patients (training study: 284 HNSCC / 122 control patients; testing study: 
141 HNSCC / 102 control patients) was quantified prior to treatment and 
longitudinally during surveillance.  
Results: In the training study, 59% of HNSCC patients were methylation-positive at 
96% specificity. Methylation levels correlated with tumor and nodal category 
(P<0.001). Initially increased methylation levels were associated with a higher risk of 
death (SEPT9: HR=5.27, P=0.001, SHOX2: HR=2.32, P=0.024). Disease 
recurrence/metastases were detected in 47% of patients up to 377 days earlier 
compared to current clinical practice. The onset of second cancers was detected up 
to 343 days earlier. In the testing study, sensitivity (52%), specificity (95%), prediction 
of overall survival (SEPT9: HR=2.78, P=0.022, SHOX2: HR=2.50, P=0.026), and 
correlation with tumor and nodal category (P<0.001) were successfully validated. 
Conclusions: Methylation testing in plasma is a powerful diagnostic tool for 
molecular disease staging, risk stratification, and disease monitoring. Patients with 
initially high biomarker levels might benefit from intensified treatment and post-
therapeutic surveillance. The early detection of a recurrent/metastatic disease or a 
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second malignancy could lead to an earlier consecutive treatment, thereby improving 
patients’ outcomes. 
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Head and neck squamous cell carcinomas (HNSCC) represent the 6th most common 
cancer worldwide with a five-year survival rate of about 65% [1]. Early-stage disease 
is managed currently with a single-modality treatment (surgery or radiotherapy), while 
advanced stages are treated using combined therapy (surgical resection and 
adjuvant radiotherapy, radio-chemotherapy or definitive radio-chemotherapy) [2]. A 
multimodal therapeutic approach is frequently accompanied by substantial side 
effects [3]. Patients with early stage tumors have an increased probability of full 
recovery, whereas patients with more advanced stages often develop loco-regional 
and/or distant recurrences [4] with a median survival of less than one year [5].  
HNSCCs display a heterogeneous tumor biology regarding risk of recurrence, 
progression, and individual tendency to metastasize. Owing to the heterogeneous 
course of the disease, there are no exact guidelines defining the therapeutic 
approach for each patient. Additional diagnostic tools for patients’ risk-stratification 
are urgently needed to achieve an effective individual treatment, while avoiding 
overtreatment. A pre-therapeutically tested blood-based biomarker might identify 
patients at a higher risk of tumor recurrence. These patients might potentially benefit 
from a more aggressive treatment, whereas patients with a better prognosis might 
benefit from a treatment with reduced toxicity. A biomarker-based, intensified clinical 
disease monitoring could lead to an early detection of recurrent or metastatic 
disease, allowing for the timely initiation of a consecutive treatment, i.e. surgery, 
radio-chemotherapy, chemotherapy, and therapies with tyrosine-kinase inhibitors 
(TKI) or therapeutic monoclonal antibodies (mAbs). Although tyrosine-kinase 
inhibitors (e.g. erlotinib and gefitinib) may cause major side effects and lack 
satisfactory efficacy [6], mAbs show promising results [7]. Cetuximab has already 
received FDA (Food and Drug Administration) approval for locally advanced, 
recurrent, and metastatic HNSCC. Immunotherapeutic treatment with the mAb 
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pembrolizumab demonstrated an overall response rate of 18% in patients with 
advanced HNSCC [8] and has very recently received FDA approval for the treatment 
of recurrent and metastatic HNSCC. The early detection of recurrent or metastatic 
disease is of particular importance in the context of immunotherapies, since late or 
delayed responses occurring after treatment initiation have been described for 
immune checkpoint inhibitors (for review: [9]), thus requiring a sufficient remaining life 
expectancy to allow for the drug to be effective.  
In addition to tumor recurrence, patients with HNSCC are at high risk of developing a 
second primary malignancy. The cumulative incidence of a second cancer within 5 
years after initial tumor diagnosis has been reported to be 17.9% [10]. A blood-based 
pan-cancer test for the detection of other malignant processes besides HNSCC might 
allow for an early diagnosis when curative treatment is still an option. 
Tumor-derived circulating cell-free DNA (ccfDNA) is a highly promising biomarker for 
the assessment of tumor progression and the evaluation of prognosis, diagnosis, and 
response to treatment [11,12,13]. Tumor cells release ccfDNA into the bloodstream; 
however, the majority of ccfDNA is hematopoietic and usually not of cancerous origin 
[14]. Tumor-specific DNA methylation allows for the discrimination of tumorous and 
non-tumorous ccfDNA.  
Septins are aberrantly expressed in several tumor entities [15]. Septin 9 has been 
shown to play a critical role in mitotic cell division [16], inhibition of proliferation, 
tumor growth, and angiogenesis [15,17]. The septin 9 (SEPT9) gene locus is 
hypermethylated in colorectal precursor lesions and carcinomas [18], and its 
methylation in ccfDNA has been proven a powerful biomarker for colorectal cancer 
screening [19] that has received FDA approval. Furthermore, SEPT9 DNA 
hypermethylation has been suggested as a biomarker for the diagnosis of HNSCC 
[20].  
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Methylation of the short stature homeobox 2 (SHOX2) gene locus is a validated lung 
cancer biomarker [21,22,23,24,25,26]. SHOX2 methylation has previously been 
shown to be associated with the amplification of the 3q25 gene locus, which is a 
frequent event in HNSCC [27,28,29]. Furthermore, SHOX2 and SEPT9 methylation 
in combination have been shown to be clinically useful diagnostic and prognostic 
biomarkers in pleural effusions and ascites [30,31]. The present study explores the 
value of quantitative SEPT9 and SHOX2 methylation levels in ccfDNA for the clinical 
management of HNSCC patients. 
 
Methods 
 
Patients and Study Design 
Patients: HNSCC patients (training cohort: n=284, testing cohort: n=141) and 
matched control patients with non-malignant diseases (training cohort: n=122, testing 
cohort: n=102) treated between July 2012 and November 2014 (training cohort) and 
between between December 2014 and July 2016 (testing cohort) at the Departments 
of Head and Neck Surgery (training and testing cohorts) and Oral and Maxillofacial 
Surgery (testing cohort) at the University Hospital of Bonn were prospectively 
enrolled.  
Inclusion/exclusion criteria: The HNSCC cohort consisted of 3 groups: 1) patients 
suffering from primary squamous cell carcinoma (SCC) of the larynx, pharynx, mouth; 
2) patients with loco-regional tumor recurrence (lymph nodes or local tissue) of a 
previous HNSCC; and 3) HNSCC patients who were clinically followed-up after 
treatment. Group 3 was included in the training cohort only. All HNSCC patients were 
free of other SCC than HNSCC for at least three years. All control patients were 
matched to HNSCC patients with respect to age, gender, and tobacco and alcohol 
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consumption. All control patients had a cancer-free history of at least three years and 
no prior history of SCC. Blood samples were taken prior to treatment and 
longitudinally during clinical follow-up.  
The study protocol was approved by the ethics committee of the University Hospital 
Bonn (vote no. 224/12). All patients provided written informed consent. 
 
 
Clinical Endpoints 
The following clinical endpoints / times-to-event were investigated: 1) death / overall 
survival; 2) development of a loco-regional recurrence (local lymph nodes or local 
tissue) / loco-regional recurrence-free survival; 3) development of distant metastases 
/ distant metastases-free survival; 4) development of a loco-regional recurrence 
and/or distant metastases / progression-free survival. Second primary cancers were 
considered as a secondary clinical endpoint. 
 
Sample Preparation and SHOX2 and SEPT9 Methylation Quantification 
Plasma was prepared from EDTA-stabilized blood and the ccfDNA was bisulfite 
converted and purified as described in detail in Supplemental Protocol 1 (all 
Supplemental information is available with the online version of this article). 
Methylation was determined using SHOX2/SEPT9/ACTB triplex qPCR as previously 
described in detail [30]. The qPCR target regions within the SHOX2 and SEPT9 
genes are shown in Supplemental Figure 1. Water was used as a no template 
control to check for cross contamination and DNA carry over. Quantitative 
methylation levels from six (plasma, 10 µl template DNA each replicate) and three 
(tissue, 20 ng quantified via UV spectrophotometry) qPCR replicates were calculated 
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using the ΔΔCq method, and mean values were computed [24,30]. The analytical 
performance of the qPCR assay has previously been evaluated [30].  
 
Statistical Analyses 
ANOVA, Kendall’s τ and Spearman’s ρ rank correlations, t-tests, and Wilcoxon-
Mann-Whitney tests were performed to compare SHOX2 and SEPT9 methylation 
levels among cancer patients and between controls and cancer patients. Median 
methylation levels were reported including Interquartile Ranges (IQR). The Area 
Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) was 
computed as a measure of test diagnostic accuracy. Cox proportional hazards 
(univariate and multivariate with backward elimination) and Kaplan-Meier analyses 
were conducted to investigate the time-to-events. P-values refer to the log rank test 
and Wald test, respectively. Two-sided P-values <0.05 were considered statistically 
significant. 
 
Results 
 
SHOX2 and SEPT9 DNA methylation in tissues and matched plasma specimens  
SHOX2 and SEPT9 were found to be hypermethylated in HNSCC tissues compared 
to normal adjacent tissues (diagnostic accuracy: AUCSEPT9=0.89, 95%CI [0.85–0.94], 
AUCSHOX2=0.98, 95%CI [0.97–0.99]; Supplemental Figure 2 in Supplemental 
Results 1). Furthermore, matched tumor samples and pre-therapeutic blood samples 
from 55 patients were analyzed. SHOX2 methylation in plasma correlated 
significantly with tissue methylation levels (Spearman’s ρ=0.36, P=0.007), and 
SEPT9 showed a trend towards higher methylation in plasma from patients with 
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SEPT9 hypermethylated tumors (Spearman’s ρ=0.25, P=0.067). Based on these 
results additional patients were recruited to build a training and a testing cohort. 
 
SHOX2 and SEPT9 DNA methylation in plasma for diagnosis and molecular staging 
A total of 284 HNSCC patients and 122 control patients with benign diseases were 
recruited for the training cohort. Baseline characteristics and distribution of clinico-
pathological data reflected a representative Caucasian cohort of HNSCC patients 
(Supplemental Table 1, Supplemental Table 2 and Table 1).  
Blood plasma samples of HNSCC patients prior to first-line treatment were available 
in 48% (137/284) of patients. Matched control patients were tested to determine the 
basal level of sporadic methylation in plasma. Quantitative levels of tumorous 
ccfDNA indicated by hypermethylation of the SHOX2 and SEPT9 gene loci were 
significantly higher in HNSCC patients compared to control patients (Figure 1A, 
AUCSEPT9=0.79, 95%CI [0.74–0.85]; AUCSHOX2=0.80, 95%CI [0.75-0.85]). The level of 
methylated ccfDNA was associated significantly with clinico-pathological tumor and 
nodal category, vascular and lymphatic invasion, and tumor grading (Table 1 and 
Supplemental Table 2). A methylation cut-off value was introduced to dichotomize 
the quantitative methylation values (Figure 1A). The cut-off was chosen based on 
the methylation levels in control patients with 95% of controls showing methylation 
levels below the cut-off (specificity). Methylation levels below these cut-offs (SHOX2: 
0.25%, SEPT9: 0.075%) were considered sporadic background methylation levels 
known to occur in blood from healthy individuals and patients with benign diseases 
[21,22,23,24]. In agreement with previous studies and as expected from the analysis 
of tissues described above, sporadic background methylation was higher for the 
SHOX2 gene locus compared to the SEPT9 gene locus [19,21,22,23,30,31]. Based 
on this cut-off, 50% (SHOX2) and 57% (SEPT9) of HNSCC patients showed a 
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positive test result (sensitivity), respectively. For diagnostic purposes, both biomarker 
levels were averaged (mean) in order to compute one value reflecting the overall 
concentration of tumorous ccfDNA better than a single biomarker. The mean 
averaged methylation level (meanSHOX2/SEPT9=[SHOX2+SEPT9]/2) resulted in 59% 
sensitivity at 96% specificity based on the mean averaged cut-off of 0.16% (Figure 
1A). A mean averaged methylation level led to an increased diagnostic accuracy 
(AUCmeanSEPT9/SHOX2=0.83, 95%CI [0.78–0.88], Figure 1A). The advantage of 
combining both biomarkers is the increase of specificity from 95% to 96%. If 
reproducible in a larger cohort, a specificity increase from 95% to 96% would mean a 
20% reduction of false positive results from 5% to 4%. Furthermore, a single value 
facilitates the application of the two biomarkers for monitoring purposes.  
 
SHOX2 and SEPT9 DNA methylation in plasma for survival prediction 
Eight out of 137 HNSCC patients with available plasma samples prior to primary 
treatment were treated in a palliative manner and thus were excluded from survival 
analyses. Due to the different biological relevance of SHOX2 and SEPT9, survival 
analyses were performed separately for each biomarker without the use of 
meanSHOX2/SEPT9. In univariate Cox proportional hazards analysis of the remaining 
129 cases, patients with positive SEPT9 and SHOX2 plasma levels were at a higher 
risk of death compared to negative patients (SEPT9: HR=5.27, 95%CI [2.03–13.68], 
P=0.001; SHOX2: HR=2.32, 95%CI [1.12–4.83], P=0.024). This finding was 
confirmed in Kaplan-Meier analyses of overall survival as shown in Figure 1B.  
To avoid overly optimistic results from the introduction of a methylation cut-off for 
result dichotomization, univariate and multivariate Cox proportional hazards analyses 
were conducted using SHOX2 and SEPT9 DNA methylation levels in plasma as 
continuous variables. In univariate Cox proportional hazards analyses, increased 
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SEPT9 methylation levels were prognostic for an adverse overall survival, a higher 
risk of loco-regional tumor recurrence, and the development of distant metastases 
(Supplemental Table 3). In multivariate Cox proportional hazards analyses including 
established prognostic factors, SEPT9 methylation proved to be an independent 
prognostic factor after backward elimination (Supplemental Table 3). SHOX2 
plasma methylation levels, in contrast, were not prognostic in multivariate analysis for 
any of the analyzed clinical endpoints (death: P=0.78, distant metastases: P=0.97; 
loco-regional recurrence: P=0.91).  
SHOX2 and SEPT9 DNA methylation in plasma: Clinical performance validation 
Selected clinical performance characteristics were validated in the testing cohort, i.e. 
diagnostic accuracy (AUCs, sensitivity, and specificity), molecular staging 
(association with T category, N category, grade), and prognostic value. A total of 141 
HNSCC patients and 102 control patients were recruited for the testing cohort. 
Baseline characteristics and distribution of clinico-pathological data of the testing 
cohort were comparable to the training cohort (Supplemental Table 4, 
Supplemental Table 5, and Table 2).  
Seventy-four of 141 HNSCC patients (sensitivity: 52%) showed a meanSHOX2/SEPT9 
plasma level above the cut-off (0.16% as defined in the training cohort) and were true 
positive, while 97 of 102 control patients (specificity: 95%) were true negative. 
MeanSHOX2/SEPT9 resulted in a diagnostic accuracy of AUC=0.80 (95%CI [0.75–0.86], 
Figure 1C). The strong correlation of SHOX2 and SEPT9 plasma hypermethylation 
with the tumor and nodal category was corroborated in the testing cohort (P<0.001 
each, Table 2). In addition, SHOX2 plasma hypermethylation was associated 
significantly with tumor grade (P=0.001). 
Four out of 141 HNSCC patients were treated in a palliative manner and thus were 
excluded from survival analyses. In univariate Cox proportional hazards analysis of 
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the remaining 137 cases, patients with positive SEPT9 and SHOX2 plasma levels 
were at higher risk of death compared to methylation-negative patients (SEPT9: 
HR=2.78, 95%CI [1.16–6.67], P=0.022; SHOX2: HR=2.50, 95%CI [1.12–5.60], 
P=0.026, Figure 1D). Accordingly, the results obtained in the training study were 
successfully validated in the testing cohort. 
 
 
SHOX2 and SEPT9 DNA methylation in plasma for disease monitoring 
Owing to the increased sensitivity and specificity noted with tandem use of both 
biomarkers (meanSEPT9/SHOX2), their combination was tested for post-therapeutic 
disease monitoring longitudinally. Plasma methylation levels during patients’ post-
therapeutic follow-up examinations were available in 90% (257/284) of patients. 
Twenty-two percent (56/257) of these patients reached one or more of the 
investigated clinical endpoints during surveillance. Twelve percent (31/257) of 
patients died, 8% (20/257) developed distant metastases, and 11% (27/257) 
relapsed loco-regionally. Distant and/or loco-regional progression of HNSCC was 
diagnosed in 17% (43/257) of patients. Furthermore, 5% (12/257) of patients 
developed a second primary tumor (four lung cancers, three HNSCC, two colorectal 
cancers, one gastric, one esophageal, and one pancreatic cancer). Seven of these 
twelve patients (58%) did not have a recurrence of the HNSCC. Thirteen percent 
(38/284) of patients had a HNSCC-specific tumor progression in absence of a 
second primary tumor. 
Plasma methylation levels of 671 blood samples from all 257 monitored patients 
were analyzed. Sixty-four (10%) blood samples were above the selected cut-point 
and therefore positive. According to 96% specificity, approximately three of these 64 
positive samples could be expected to be false positive results. Altogether, 16% 
(42/257) of patients showed one or more positive results. Of these patients, 62% 
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(26/42) had a single positive result, 31% (13/42) had two positive blood samples, and 
7% (3/42) of patients had more than two positive results. Supplemental Table 6 
shows the results from the last negative and the first positive blood samples from all 
patients who reached one or more of the clinical endpoints during disease 
monitoring. All patients (n=16) with more than one positive test result reached one or 
more of the clinical endpoints. Of patients with only one positive test result, 92% 
(24/26) suffered from a disease progression or a second cancer and/or died within 
one year after the first positive blood test, which is in line with the specificity of the 
test. Deceased patients had a positive biomarker testing in 18/31 (58%) cases. The 
test positivity occurred a mean of 213 (range: 30–488) days before death. However, 
seven patients (Supplemental Table 6) showed high methylation levels in plasma 
prior to death without any diagnosed tumor recurrence or second primary cancer. 
Methylation levels in plasma above the cut-off were found in 47% (18/38) of patients 
with a loco-regional or a distant tumor recurrence in the absence of a second primary 
tumor. Of these patients, 78% (14/18) had a positive test result a mean of 105 (range 
8-377) days before the clinico-pathological verification of the tumor progression. The 
tumor recurrence of the other four patients (4/18) was diagnosed on the day of 
treatment, as patients were not available for testing beforehand. In detail, 43% (6/14) 
developed a loco-regional recurrence, 43% (6/14) a distant recurrence, and 14% 
(2/14) both. Two patients who developed a second primary cancer in the absence of 
a HNSCC-specific tumor recurrence (n=7) showed a suspicious increase in 
biomarker levels 112 days (ductal pancreatic adenocarcinoma) and 343 days 
(oesophageal cancer) prior to the clinico-pathological diagnosis of the second 
cancer. Monitoring results from eight selected cases are described in detail in 
Supplemental Results 2. 
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Discussion 
Previously, the therapeutic approach for HNSCC patients has mainly relied on clinical 
staging parameters. However, there are no validated guidelines defining the exact 
treatment of HNSCC. Powerful biomarkers are therefore urgently needed to enable 
precise and reliable diagnosis, treatment, and prognosis, particularly in the context of 
novel therapeutic options, e.g. immunotherapies.  
The aggressiveness of adjuvant treatment has been controversial and a topic of 
frequent discussions. Novel prognostic factors besides clinical tumor staging might 
improve risk stratification and lead to more personalized therapy. SHOX2 and SEPT9 
proved to be powerful prognostic and molecular staging biomarkers for identifying 
patients at higher risk of tumor recurrence. Consequently, patients with high 
methylation levels prior to therapy would benefit from a more aggressive first-line 
therapy and should receive more intensified post-therapeutic disease monitoring. Of 
note, in contrast to strong prognostic parameters, i.e. pathologic tumor and nodal 
category, SEPT9 and SHOX2 methylation in blood are accessible prior to a surgical 
resection of the tumor, thus providing a chance to adapt first-line treatment in 
accordance with the prognosis of the patient. Currently, neoadjuvant 
immunotherapies are under investigation which might represent an option for patients 
who are unlikely to benefit from a surgery with curative intent. 
Following treatment, the timely detection of disease recurrence or metastases is of 
particular importance. The rapid development of novel immunotherapies, in 
particular, implies treatment options even for patients with an advanced or metastatic 
disease [8]. However, immunotherapies require a minimal remaining life expectation 
to be effective. Accordingly, the earlier detection of an incurable disease is likely to 
increase the quality-adjusted life span of these patients. Just as with the treatment of 
HNSCC, there are no validated guidelines defining the intervals and the exact 
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procedure of post-therapeutic follow-up examinations. To evaluate the impact of 
SHOX2 and SEPT9 in post-therapeutic monitoring, biomarker levels in blood plasma 
were investigated longitudinally during follow-up examinations. The sensitivity of the 
biomarkers for the detection of tumor recurrences was only slightly lower compared 
to the sensitivity of the detection of the primary HNSCC. In test-positive patients with 
tumor recurrences, suspicious biomarker levels were found significantly earlier 
compared to the common clinical practice. However, shorter time intervals between 
biomarker testing during follow-up care could lead to an even higher efficiency of 
such a test. In this study cohort, seven patients showed high methylation levels in 
plasma prior to death without any diagnosed tumor recurrence or development of a 
second primary cancer. Owing to the high specificity of the biomarkers (95-96%), it 
can be speculated that an occult tumor progression was present in these cases. 
Unfortunately, body-imaging examinations that could have clarified the status of 
these patients were not feasible. Several patients with a post-therapeutic positive 
blood sample were retested over time. Those with positive results in consecutively 
taken blood samples proved to suffer from disease progression in all cases, whereas 
only 92% of patients with only one positive test result had a proven tumor recurrence. 
Accordingly, the retesting of a positive blood sample using a second blood specimen 
is likely to increase the specificity of the monitoring test. The performance of the 
monitoring test might further be improved by individualizing the algorithm for the 
results interpretation based on the analysis of the tumor tissue or based on the 
inclusion of the pre-therapeutic blood test result. Patients whose tumor or pre-
therapeutic blood sample is positive for only either SEPT9 or SHOX2 might benefit 
from a monitoring test that considers only the positive biomarker for the interpretation 
of the result.   
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SHOX2 and SEPT9 DNA hypermethylation additionally has been linked to other 
cancers associated with alcohol and tobacco consumption (i.e. tumors of the lung, 
colon, stomach, liver, biliary tract and pancreas) [18,19,22,30,31,32] and could 
therefore be a promising biomarker candidate for the detection of occult second 
primary cancers during disease monitoring of HNSCC. Furthermore, these 
biomarkers might be a potential diagnostic tool for the management of malignant 
diseases other than HNSCC, as they appear to be non-specific regarding tumor-site 
and organ. 
The use of ccfDNA for cancer screening purposes is controversial. This study 
indicates that neither of these biomarkers is well suited for HNSCC screening owing 
to three major shortcomings: 1) Even a relatively high specificity of 95-96% results in 
a positive predictive value (PPV) that is too low leading to additional effort and costs 
for validation of patients with positive screening results; 2) The sensitivity of the 
investigated biomarkers is higher for advanced tumor stages compared with early 
stage cancers. Accordingly, small and clinically occult tumors that would have the 
highest chance of cure are likely to be missed; 3) The group of individuals with a high 
risk profile of developing HNSCC (main risk factors: alcohol consumption and 
smoking) usually do not exhibit health-conscious behavior and therefore would 
probably not participate in a screening program. The latter limitation, however, is a 
general problem regarding HNSCC patients and is not related to the clinical 
performance of a biomarker. 
In conclusion, this study demonstrates that quantitative SEPT9 and SHOX2 DNA 
methylation levels in ccfDNA from blood plasma are clinically valuable biomarkers for 
diagnosis, molecular staging, prognosis (risk-stratification), and post-therapeutic 
monitoring of HNSCC patients. However, overdiagnosis is a common problem in 
clinical oncology and needs to be avoided [33]. Accordingly, a multicenter, 
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randomized, prospective, and interventional study is being currently planned that will 
investigate whether the application of such biomarkers leads to an improved survival 
with a high quality of life or to a reduction of costs. 
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Figure Legends 
 
 
Figure 1: A: Training cohort: SHOX2, SEPT9 and averaged 
(meanSHOX2/SEPT9=[SHOX2+SEPT9]/2) DNA methylation levels in plasma from 
HNSCC (n=137) and control patients (n=122) and diagnostic accuracy (ROC 
analysis). B: Training cohort: Kaplan-Meier survival analysis of 129 HNSCC patients 
treated with curative intent stratified according to plasma methylation levels. C: 
Diagnostic accuracy in the validation cohort (n=141 HNSCC and n=102 control 
patients). D: Validation cohort: Kaplan-Meier survival analysis of 137 HNSCC 
patients treated with curative intent. 
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Tables 
 
Table 1: Association of methylation levels with stage and histological grade 
(training cohort). T and N categories and histological grade of the 284 cancer cases 
included in the HNSCC patient cohort and their association with SHOX2 and SEPT9 
plasma DNA methylation levels. Methylation levels in plasma prior to treatment were 
available for 137/284 patients. A comprehensive list of methylation levels and their 
association with clinico-pathologic parameters (T-, N-, M-category, grade, tumor 
localization, vascular invasion (V), lymphatic invasion (L), surgical margin (R), and 
tumor status (primary tumor versus recurrence)) can be found in Supplemental Table 
2. 
 
   Methylation in Plasma Prior to Treatment 
Clinico-pathologic 
Parameters 
Total Number 
(n) 
 n 
Median 
SEPT9 [%]; 
IQR 
P-Value
‡
 
Median 
SHOX2 [%]; 
IQR 
P-Value
‡ 
 
All HNSCC Cases 284 (100%)  137 (100%) 0.14; 0.87  0.25; 0.94  
        
T-Stage        
Tis 9 (3%)  1 (1%) 0.00; N/A  0.05; N/A  
T1 65 (23%)  22 (16%) 0.00; 0.10  0.03; 0.10  
T2 87 (31%)  42 (31%) 0.13; 0.65  0.27; 1.40  
T3 56 (20%)  30 (22%) 0.07; 0.63  0.18; 0.78  
T4 48 (17%)  32 (23%) 0.76; 1.90 P<0.001
†
 0.72; 2.21 P<0.001
†
 
N/A
¥
  19 (7%)  10 (7%) 0.04; 2.31  0.37; 2.25  
        
Nodal Status        
N0 110 (39%)  37 (27%) 0.07; 0.32  0.12; 0.35  
N1 35 (12%)  19 (14%) 0.09; 1.40  0.31; 0.67  
N2 89 (31%)  51 (37%) 0.56; 1.08  0.45; 2.66  
N3 6 (2%)  2 (1%) 4.57; N/A P<0.001
†
 14.72; N/A P<0.001
†
 
Nx 44 (16%)^ 
 
 
 
 
 
 28 (20%) 0.00; 0.27  0.05; 0.56  
        
Histopathological Grade        
G1 9 (3%)  2 (1%) 0.00; N/A  0.03; N/A  
G2 127 (45%)  59 (43%) 0.09; 0.50  0.13; 0.42  
G3 85 (30%)  51 (37%) 0.24; 1.20 P=0.027
†
 0.52; 3.15 P<0.001
†
 
N/A
¥
 63 (22%)  25 (18%) 0.06; 1.50  0.25; 0.97  
 
 
 
       
 
 
¥
 N/A: not applicable or unknown because no surgical specimen analyzed (palliative treatment / supportive care, concurrent 
radio-chemotherapy) or data not available. TNM classification does not apply to CUP and local lymph node recurrences. 
Grading does not apply to CUP and loco-regional recurrences.  
‡
 P-values refer to Kendall’s τ rank correlation. 
†
 Significant feature 
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Table 2: Association of methylation levels with stage and histological grade 
(testing cohort). T and N categories and histological grade of 141 cancer cases 
included in the HNSCC patient testing cohort and their association with pre-
therapeutic SHOX2 and SEPT9 plasma DNA methylation levels. A comprehensive 
list of methylation levels and their association with clinico-pathologic parameters (T-, 
N-, M-category, grade, tumor localization, vascular invasion (V), lymphatic invasion 
(L), surgical margin (R), and tumor status (primary tumor versus recurrence)) can be 
found in Supplemental Table 4. 
 
 Methylation in Plasma Prior to First-line Treatment 
Clinico-pathologic 
Parameters 
n 
Median SEPT9 
[%]; IQR 
P-Value
‡
 
Median SHOX2 
[%]; IQR 
P-Value
‡ 
 
All HNSCC Cases 141 (100%) 0.10; 0.80  0.20; 0.72  
      
T-category      
Tis 1 (1%) 0.00; N/A  0.05; N/A  
T1 31 (22%) 0.00; 0.08  0.05; 0.15  
T2 43 (30%) 0.17; 0.67  0.12; 1.19  
T3 29 (21%) 0.13; 0.54  0.23; 0.75  
T4 28 (20%) 0.93; 2.02 P<0.001
†
 0.50; 0.66 P<0.001
†
 
N/A
¥
  9 (6%) 0.00; 0.45  0.20; 5.63  
      
Nodal Status      
N0 38 (27%) 0.00; 0.22  0.07; 0.29  
N1 24 (17%) 0.09; 0.50  0.07; 0.30  
N2 54 (38%) 0.32; 1.33  0.37; 2.15  
N3 5 (4%) 2.22; 13.23 P<0.001
†
 2.40; 3.94 P<0.001
†
 
Nx 20 (14%) 0.02; 0.56  0.21; 0.52  
      
Histopathological Grade      
G1 10 (7%) 0.00; 0.67  0.03; 0.14  
G2 52 (37%) 0.12; 0.46  0.08; 0.35  
G3 33 (23%) 0.10; 1.33 P=0.13 0.45; 1.53 P=0.001
†
 
N/A
¥
 46 (33%) 0.17; 0.82  0.29; 1.00  
¥
 N/A: not applicable or unknown because no surgical specimen analyzed (palliative treatment / supportive care, concurrent 
radio-chemotherapy) or data not available. TNM classification does not apply to CUP and local lymph node recurrences. 
Grading does not apply to CUP and loco-regional recurrences.  
‡
 P-values refer to Kendall’s τ rank correlation. 
†
 Significant feature 
 26 
Supplemental Table 1: Patients’ characteristics (training cohort). Characteristics of the HNSCC 
patient cohort (284 patients) and matched group of control patients (122 individuals). First-line 
treatment of HNSCC patients consisted of surgery in 32% (90/284), surgery and adjuvant radio-
(chemo)therapy in 60% (171/284), or definitive radio-chemotherapy in 8% (23/284). 
 Total  HNSCC Cohort  Matched Controls 
Age 406 (100%)  284 (100%)  122 (100%) 
      
≤ 50 Years 50 (13%)  30 (11%)  20 (16%) 
51-60 Years 139 (34%)  97 (34%)  42 (35%) 
> 60 Years 217 (53%)  157 (55%)  60 (49%) 
Median Age [Years] 61  61  60 
Mean Age [Years] 61.4  61.4  61.4 
Age Range [Years] 32-89  32-89  32-87 
      
Gender      
Female 80 (20%)  53 (19%)  27 (22%) 
Male 326 (80%)  231 (81%)  95 (78%) 
      
Smoking and Drinking Habits      
Non-smokers 40 (10%)  30 (10%)  10 (8%) 
Smokers (Current and Former) 309 (76%)  215 (76%)  94 (77%) 
Unknown Smoking Status 57 (14%)  39 (14%)  18 (15%) 
Range Pack/Years 0-200  0-200  0-120 
Median Pack/Years (Smokers only) 40  40  35 
Mean Pack/Years (Smokers only) 42.0  44.1  37.1 
Unknown Alcohol Consumption 76 (18%)  49 (18%)  27 (22%) 
No Alcohol 32 (8%)  26 (9%)  6 (5%) 
Occasional Alcohol 60 (15%)  40 (14%)  20 (16%) 
Moderate Alcohol 157 (39%)  99 (35%)  58 (47%) 
Strong Alcohol 32 (8%)  27 (9%)  5 (4%) 
Alcoholic (Current and Former) 49 (12%)  43 (15%)  6 (5%) 
      
Pre-existing Conditions      
None 56 (14%)  52 (18%)  4 (3%) 
Diseases of Inner Ear, Equilibrium Organ and Middle 
Ear 
40 (5%)  10 (4%)  30 (25%) 
Diseases of Nose and Paranasal Sinuses 30 (10%)  0 (0%)  30 (25%) 
Diseases of Oral Cavity, Larynx and Salivary Glands 1 (<1%)  0 (0%)  1 (1%) 
Expanding Lesions Throat  19 (5%)  1 (<1%)  18 (15%) 
Leucoplakia, Erythroplakia, Ulcers 5 (1%)  1 (<1%)  4 (3%) 
Acute ENT-Infections und Abscesses 11 (3%)  2 (1%)  9 (7%) 
Benign ENT-Tumors 8 (2%)  1 (<1%)  7 (6%) 
Diseases of Gastrointestinal Tract 60 (15%)  48 (17%)  12 (10%) 
Diseases of Cardiovascular System 200 (49%)  144 (51%)  56 (46%) 
Diseases of Respiratory System 52 (13%)  40 (14%)  12 (10%) 
Diseases of Metabolism or Endocrinological System 115 (28%)  83 (29%)  32 (26%) 
Diseases of Kidney and Urinary Tract 17 (4%)  10 (4%)  7 (6%) 
Diseases of Hepatic and Biliary System 20 (5%)  17 (6%)  3 (2%) 
Infectious Diseases 3 (1%)  2 (1%)  1 (1%) 
Ophthalmologic Diseases 4 (1%)  3 (1%)  1 (1%) 
Skin Diseases 10 (2%)  5 (2%)  5 (4%) 
Skeletal Diseases 35 (9%)  24 (8%)  11 (9%) 
Neurological and Psychiatric Diseases 43 (11%)  32 (11%)  11 (9%) 
Status after Other Malignant Tumors 21 (5%)*  18 (6%)  3 (2%) 
Status after Other Benign Tumors (Excl. ENT Tumors) 3 (1%)  2 (1%)  1 (1%) 
 
* Cases: breast cancer (n=1), uterine cancer (n=3), prostate cancer (n=1), colorectal cancer (n=1), esophageal cancer (n=2), 
lung cancer (n=3), CLL (n=1), multiple myeloma (n=1), basalioma (n=4); controls: prostate cancer (n=1), basalioma (n=2) 
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Supplemental Table 2: Clinico-pathologic parameters and methylation levels (training cohort). 
Clinico-pathologic parameters of the 284 cancer cases included in the HNSCC patient cohort and the 
association with SHOX2 and SEPT9 plasma DNA methylation levels. Methylation levels in plasma 
prior to treatment were available for 137/284 patients. 
   Methylation in Plasma Prior to Treatment 
Clinico-pathologic Parameters 
Total 
Number (n) 
 n 
Median SEPT9 
[%]; IQR 
P-Value
‡
 
Median 
SHOX2 [%]; 
IQR 
P-Value
‡ 
 
All HNSCC Cases 284 (100%)  137 (100%) 0.14; 0.87  0.25; 0.94  
        
Localisation        
Oral Cavity / Tongue / Lips 34 (12%)  15 (11%) 0.16; 0.74  0.30; 1.14  
Oropharynx and Tonsils 107 (38%)  53 (39%) 0.23; 1.04  0.27; 2.00  
Hypopharynx 26 (9%)  18 (13%) 0.09; 0.88  0.52; 4.64  
Larynx 92 (32%)  37 (27%) 0.05; 0.46  0.12; 0.45  
Others (Nasopharynx, Facial Skin) 18 (6%)  10 (7%) 0.86; 1.97  0.27; 0.92  
CUP 8 (3%)  4 (3%) 0.00; 1.20 P=0.46 0.36; 1.48 P=0.51 
        
Tumor        
Primary Tumor 235 (83%)  107 (78%) 0.14; 0.81  0.28; 1.33  
Loco-regional Recurrence 50 (18%)  30 (22%) 0.12; 1.20 P=0.66 0.11; 0.64 P=0.075 
        
T-Stage        
Tis 9 (3%)  1 (1%) 0.00; N/A  0.05; N/A  
T1 65 (23%)  22 (16%) 0.00; 0.10  0.03; 0.10  
T2 87 (31%)  42 (31%) 0.13; 0.65  0.27; 1.40  
T3 56 (20%)  30 (22%) 0.07; 0.63  0.18; 0.78  
T4 48 (17%)  32 (23%) 0.76; 1.90 P<0.001
†
 0.72; 2.21 P<0.001
†
 
N/A
¥
  19 (7%)  10 (7%) 0.04; 2.31  0.37; 2.25  
        
Nodal Status        
N0 110 (39%)  37 (27%) 0.07; 0.32  0.12; 0.35  
N1 35 (12%)  19 (14%) 0.09; 1.40  0.31; 0.67  
N2 89 (31%)  51 (37%) 0.56; 1.08  0.45; 2.66  
N3 6 (2%)  2 (1%) 4.57; N/A P<0.001
†
 14.72; N/A P<0.001
†
 
Nx 44 (16%)  28 (20%) 0.00; 0.27  0.05; 0.56  
        
Distant Metastases        
M0 279 (98%)  132 (96%) 0.12; 0.80  0.23; 0.78  
M1 5 (2%)  5 (4%) 1.56; 4.16 P=0.32 3.09; 26.62 P=0.022
†
 
        
Histopathological Grade        
G1 9 (3%)  2 (1%) 0.00; N/A  0.03; N/A  
G2 127 (45%)  59 (43%) 0.09; 0.50  0.13; 0.42  
G3 85 (30%)  51 (37%) 0.24; 1.20 P=0.027
†
 0.52; 3.15 P<0.001
†
 
N/A
¥
 63 (22%)  25 (18%) 0.06; 1.50  0.25; 0.97  
        
Lymphatic Invasion        
L0 132 (47%)  64 (46%) 0.15; 0.79  0.17; 0.67  
L1 38 (13%)  28 (21%) 0.19; 0.74 P=0.83 0.43; 2.30 P=0.043
†
 
N/A
¥
 114 (40%)  45 (33%) 0.06; 1.28  0.25; 1.89  
        
Vascular Invasion        
V0 154 (54%)  79 (58%) 0.15; 0.72  0.21; 0.68  
V1 17 (6%)  12 (9%) 0.87; 1.93 P=0.038
†
 0.83; 2.21 P=0.047
†
 
N/A
¥
 113 (40%)  46 (34%) 0.05; 1.19  0.23; 1.81  
        
Surgical Margin        
R0 182 (64%)  83 (61%) 0.15; 0.73  0.20; 0.65  
R1 27 (9%)  19 (14%) 0.71; 1.41  0.83; 3.25  
R2 2 (1%)  2 (1%) 1.00; N/A P=0.090 0.78; N/A P=0.014
†
 
N/A
¥
 73 (26%)  33 (24%) 0.04; 0.89  0.21; 1.63  
¥
 N/A: not applicable or unknown because no surgical specimen analyzed (palliative treatment / supportive care, concurrent 
radio-chemotherapy) or data not available. TNM classification does not apply to CUP and local lymph node recurrences. 
Grading does not apply to CUP and loco-regional recurrences.  
‡
 P-values refer to the following tests: Wilcoxon-Mann-Whitney test (R0 vs. R1,2; L0 vs. L1; V0 vs. V1; M0 vs. M1; primary tumor vs. 
loco-regional Recurrence), Kendall’s τ rank correlation (T stage, N stage, grade), ANOVA (tumor localization). 
†
 Significant feature 
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Supplemental Table 3: Survival analyses (training cohort). Univariate and multivariate Cox 
proportional hazards regression of overall, distant metastases-free, loco-regional recurrence-free, and 
progression-free survival for SEPT9 DNA methylation levels (as continuous variable), tumor category 
(T), nodal category (N), vascular invasion (V), lymphatic invasion (L), grade (G), tumor status (primary 
tumor or loco-regional recurrence of an earlier HNSCC). Patients receiving only palliative treatment or 
supportive care were excluded from survival analyses. 
   Univariate  Multivariate  
S
u
rv
iv
a
l 
/ 
T
im
e
-t
o
-
E
v
e
n
t 
Clinico-pathologic Factor n 
E
v
e
n
ts
 
C
e
n
s
o
re
d
 
P-value 
Hazard Ratio 
[95% CI] 
 P-value 
Hazard Ratio 
[95% CI] 
O
v
e
ra
ll
 S
u
rv
iv
a
l 
T4, T3, T2, T1, Tis 123 33 90 0.001
†
 1.84 [1.30 – 2.60]  0.050 1.82 [1.00 – 3.29] 
N3, N2, N1, N0 103 26 77 0.16 1.35 [0.89 – 2.04]    
G3, G2, G1 110 27 83 0.24 1.52 [0.75 – 3.05]    
L1 vs. L0 91 25 66 0.25 1.60 [0.72 – 3.56]    
V1 vs. V0 90 25 65 0.004
†
 3.83 [1.56 – 9.43]  0.011
†
 4.27 [1.40 – 13.1] 
R2,1 vs. R0 102 25 77 0.001
†
 3.69 [1.67 – 8.16]    
Loco-regional Recurrence vs. 
Primary Tumor  
129 33 96 0.025
†
 1.34 [1.04 – 1.72]    
SEPT9 Methylation  129 33 96 <0.001
†
 1.14 [1.07 – 1.22]  0.005
†
 1.23 [1.07 – 1.41] 
D
is
ta
n
t 
M
e
ta
s
ta
s
e
s
-f
re
e
 S
u
rv
iv
a
l T4, T3, T2, T1, Tis 123 16 107 0.021 1.78 [1.09 – 2.91]    
N3, N2, N1, N0 103 14 89 0.22 1.42 [0.81 – 2.50]    
G3, G2, G1 110 15 95 0.70 1.20 [0.48 – 3.00]    
L1 vs. L0 91 13 78 0.21 2.02 [0.68 – 6.01]    
V1 vs. V0 90 13 77 0.91 0.89 [0.12 – 6.88]    
R2,1 vs. R0 102 13 89 0.45 1.65 [0.45 – 6.00]    
Loco-regional Recurrence vs. 
Primary Tumor 
129 17 112 0.19 1.29 [0.88 – 1.88]    
SEPT9 Methylation  129 17 112 0.002
†
 1.28 [1.09 – 1.50]  0.012
†
 1.25 [1.05 – 1.49] 
L
o
c
o
-r
e
g
io
n
a
l 
R
e
c
u
rr
e
n
c
e
-f
re
e
 
S
u
rv
iv
a
l 
T4, T3, T2, T1, Tis 123 19 104 0.60 1.12 [0.73 – 1.72]    
N3, N2, N1, N0 103 16 87 0.49 0.83 [0.49 – 1.41]    
G3, G2, G1 110 15 95 0.27 0.60 [0.24 – 1.49]    
L1 vs. L0 91 15 76 0.38 0.57 [0.16 – 2.01]    
V1 vs. V0 90 15 75 0.64 0.62 [0.08 – 4.71]    
R2,1 vs. R0 102 14 88 0.60 1.41 [0.39 – 5.08]    
Loco-regional Recurrence vs. 
Primary Tumor 
129 21 108 0.001
†
 1.64 [1.22 – 2.20]  0.024
†
 1.72 [1.07 – 2.76] 
SEPT9 Methylation  129 21 108 <0.001
†
 1.21 [1.10 – 1.33]  0.005
†
 1.32 [1.09 – 1.59] 
P
ro
g
re
s
s
io
n
-f
re
e
 S
u
rv
iv
a
l 
T4, T3, T2, T1, Tis 123 32 91 0.16 1.27 [0.91 – 1.78]    
N3, N2, N1, N0 103 27 76 1.00 1.00 [0.67 – 1.48]    
G3, G2, G1 110 27 83 0.43 0.61 [0.43 – 1.64]    
L1 vs. L0 91 26 65 0.95 1.03 [0.45 – 2.37]    
V1 vs. V0 90 26 64 0.71 0.76 [0.18 – 3.21]    
R2,1 vs. R0 102 25 77 0.99 1.00 [0.34 – 2.92]    
Loco-regional Recurrence vs. 
Primary Tumor 
129 35 94 <0.001
†
 1.57 [1.24 – 2.00]  0.008
†
 1.68 [1.14 – 2.48] 
SEPT9 Methylation  129 35 94 <0.001
†
 1.21 [1.11 – 1.33]  0.002
†
 1.19 [1.10 – 1.56] 
 
†
 Significant feature 
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Supplemental Table 4: Patients’ characteristics (testing cohort). Characteristics of the HNSCC 
patient testing cohort (141 patients) and matched group of control patients (102 individuals). First-line 
treatment of HNSCC patients consisted of surgery in 31% (44/141), surgery and adjuvant radio-
(chemo)therapy in 53% (75/141), or definitive radio-chemotherapy in 16% (22/141). 
 Total  HNSCC Cohort  Matched Controls 
Age 243 (100%)  141 (100%)  102 (100%) 
      
≤ 50 Years 24 (10%)  11 (8%)  13 (13%) 
51-60 Years 67 (28%)  37 (26%)  30 (29%) 
> 60 Years 152 (63%)  93 (66%)  59 (58%) 
Median Age [Years] 63  63  62 
Mean Age [Years] 63.6  64.5  62.6 
Age Range [Years] 36-83  37-93  36-86 
      
Gender      
Female 57 (23%)  26 (18%)  31 (30%) 
Male 186 (77%)  115 (82%)  71 (70%) 
      
Smoking and Drinking Habits      
Non-smokers 50 (21%)  28 (20%)  22 (22%) 
Smokers (Current and Former) 175 (72%)  103 (73%)  72 (71%) 
Unknown Smoking Status 18 (7%)  10 (7%)  8 (8%) 
Range Pack/Years 0-130  0-130  0-100 
Median Pack/Years (Smokers only) 30  30  30 
Mean Pack/Years (Smokers only) 31.6  31.2  31.9 
Unknown Alcohol Consumption 26 (11%)  13 (9%)  13 (13%) 
No Alcohol 43 (18%)  28 (20%)  15 (15%) 
Occasional Alcohol 43 (18%)  19 (13%)  24 (24%) 
Moderate Alcohol 73 (30%)  36 (26%)  37 (36%) 
Strong Alcohol 11 (4%)  5 (4%)  6 (6%) 
Alcoholic (Current and Former) 47 (19%)  40 (28%)  7 (7%) 
      
Pre-existing Conditions      
None 30 (12%)  25 (18%)  5 (5%) 
Diseases of Inner Ear, Equilibrium Organ and Middle 
Ear 
38 (16%)  5 (4%)  33 (32%) 
Diseases of Nose and Paranasal Sinuses 26 (11%)  0 (0%)  26 (25%) 
Diseases of Oral Cavity, Larynx and Salivary Glands 0 (0%)  0 (0%)  0 (0%) 
Expanding Lesions Throat  21 (9%)  1 (1%)  20 (20%) 
Leucoplakia, Erythroplakia, Ulcers 18 (7%)  7 (5%)  11 (11%) 
Acute ENT-Infections und Abscesses 15 (6%)  0 (0%)  15 (15%) 
Benign ENT-Tumors 15 (6%)  1 (1%)  14 (14%) 
Diseases of Gastrointestinal Tract 33 (14%)  25 (18%)  8 (8%) 
Diseases of Cardiovascular System 183 (75%)  114 (81%)  69 (68%) 
Diseases of Respiratory System 48 (20%)  26 (18%)  22 (22%) 
Diseases of Metabolism or Endocrinological System 50 (21%)  26 (18%)  24 (24%) 
Diseases of Kidney and Urinary Tract 19 (8%)  15 (11%)  4 (4%) 
Diseases of Hepatic and Biliary System 13 (5%)  7 (5%)  6 (6%) 
Infectious Diseases 2 (1%)  2 (1%)  0 (0%) 
Ophthalmologic Diseases 5 (2%)  4 (3%)  1 (<1%) 
Skin Diseases 14 (6%)  5 (4%)  9 (9%) 
Skeletal Diseases 24 (10%)  7 (5%)  17 (17%) 
Neurological and Psychiatric Diseases 34 (14%)  20 (14%)  14 (14%) 
Status after Other Malignant Tumors 25 (10%)*  12 (9%)  13 (13%) 
Status after other Benign Tumors (Excl. ENT Tumors) 4 (2%)  3 (2%)  1 (1%) 
 
* Cases: breast cancer (n=3), uterine cancer (n=4), prostate cancer (n=3), colorectal cancer (n=1), CLL (n=1); controls: breast 
cancer (n=2), uterine cancer (n=3), prostate cancer (n=1), thyroid carcinoma (n=2), colorectal cancer (n=1), CLL (n=2), 
basalioma (n=2) 
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Supplemental Table 5: Clinico-pathologic parameters and methylation levels (testing cohort). 
Clinico-pathologic parameters of 141 cancer cases included in the HNSCC patient testing cohort and 
association with pre-therapeutic SHOX2 and SEPT9 plasma DNA methylation levels. 
 Methylation in Plasma Prior to First-line Treatment 
Clinico-pathologic Parameters n 
Median SEPT9 
[%]; IQR 
P-Value
‡
 
Median SHOX2 
[%]; IQR 
P-Value
‡ 
 
All HNSCC Cases 141 (100%) 0.10; 0.80  0.20; 0.72  
      
Localisation      
Oral Cavity / Tongue / Lips 38 (27%) 0.08; 0.79  0.14; 0.48  
Oropharynx and Tonsils 41 (29%) 0.23; 1.53  0.23; 2.37  
Hypopharynx 17 (12%) 0.08; 1.13  0.48; 0.95  
Larynx 33 (23%) 0.05; 0.39  0.07; 0.32  
Others (Nasopharynx, Facial Skin) 9 (6%) 0.03; 1.48  0.31; 1.13  
CUP 3 (2%) 0.47; N/A P=0.097 0.23; N/A P=0.20 
      
Tumor      
Primary Tumor 112 (79%) 0.16; 0.83  0.22; 0.81  
Loco-regional Recurrence 29 (21%) 0.05; 0.45 P=0.41 0.09; 0.45 P=0.30 
      
T-category      
Tis 1 (1%) 0.00; N/A  0.05; N/A  
T1 31 (22%) 0.00; 0.08  0.05; 0.15  
T2 43 (30%) 0.17; 0.67  0.12; 1.19  
T3 29 (21%) 0.13; 0.54  0.23; 0.75  
T4 28 (20%) 0.93; 2.02 P<0.001
†
 0.50; 0.66 P<0.001
†
 
N/A
¥
  9 (6%) 0.00; 0.45  0.20; 5.63  
      
Nodal Status      
N0 38 (27%) 0.00; 0.22  0.07; 0.29  
N1 24 (17%) 0.09; 0.50  0.07; 0.30  
N2 54 (38%) 0.32; 1.33  0.37; 2.15  
N3 5 (4%) 2.22; 13.23 P<0.001
†
 2.40; 3.94 P<0.001
†
 
Nx 20 (14%) 0.02; 0.56  0.21; 0.52  
      
Distant Metastases      
M0 138 (98%) 0.10; 0.82  0.20; 0.72  
M1 3 (2%) 0.00; N/A P=0.53 0.06; N/A P=1.0
†
 
      
Histopathological Grade      
G1 10 (7%) 0.00; 0.67  0.03; 0.14  
G2 52 (37%) 0.12; 0.46  0.08; 0.35  
G3 33 (23%) 0.10; 1.33 P=0.13 0.45; 1.53 P=0.001
†
 
N/A
¥
 46 (33%) 0.17; 0.82  0.29; 1.00  
      
Lymphatic Invasion      
L0 69 (49%) 0.09; 0.90  0.10; 0.51  
L1 29 (21%) 0.14; 0.53 P=0.45 0.12; 1.67 P=0.46 
N/A
¥
 43 (30%) 0.26; 0.82  0.27; 0.93  
      
Vascular Invasion      
V0 86 (61%) 0.09; 0.53  0.10; 0.55  
V1 9 (6%) 0.23; 1.34 P=0.47 0.09; 0.94 P=0.93 
N/A
¥
 46 (33%) 0.17; 0.84  0.30; 1.01  
      
Surgical Margin      
R0 90 (64%) 0.09; 0.70  0.15; 0.71  
R1 11 (8%) 0.01; 0.18  0.06; 0.12  
R2 2 (1%) 5.65; N/A P=0.71 24.44; N/A P=0.35 
N/A
¥
 38 (27%) 0.27; 0.91  0.29; 1.28  
¥
 N/A: not applicable or unknown because no surgical specimen analyzed (palliative treatment / supportive care, concurrent 
radio-chemotherapy) or data not available. TNM classification does not apply to CUP and local lymph node recurrences. 
Grading does not apply to CUP and loco-regional recurrences.  
‡
 P-values refer to the following tests: Wilcoxon-Mann-Whitney test (R0 vs. R1,2; L0 vs. L1; V0 vs. V1; M0 vs. M1; primary tumor vs. 
loco-regional Recurrence), Kendall’s τ rank correlation (T stage, N stage, grade), ANOVA (tumor localization). 
†
 Significant feature 
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Supplemental Table 6: Disease monitoring. Results of the last negative and first positive blood 
tests are shown where applicable. The difference between the day of the clinical endpoints (or the 
diagnosis of a second cancer) and the day of the first positive blood test were calculated. A positive 
time difference indicates an earlier diagnosis via DNA methylation biomarkers compared to standard 
diagnostic work-up. Results are shown from all study patients who reached one or more clinical 
endpoints. Only patients with at least one blood sample available during follow-up are listed. 
 Test Result [Day* of 
Testing / Test Result] 
 Day* of Reaching Clinical Endpoint   Difference [Day* of Reaching Clinical 
Endpoint – Day* of First Positive Test 
Result] 
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1 30 / 0.05 x  144  77 77   x  x x  
2 37 / 0.01 x  215  78 78   x  x x  
3 44 / 0.03 50 / 0.71  195      145     
4 13 / 0.04 61 / 10.89  166  83 83   105  22 22  
5 6 / 0.01 62 / 1.22  228      166     
6 28 / 0.15 x  165      x     
7 x 36 / 11.04  275 241 29 29   239 205 -7 -7  
8 4 / 0.04 x  361  113 113   x  x x  
9 8 / 0.03 83 / 0.85  209      126     
10 19 / 0.01 x  76      x     
11 384 / 0.01 475 / 1.19  734 126  126   259 -349  -349  
12 13 / 0.04 x  293  110 110   x  x x  
13 14 / 0.13 204 / 0.30  525      321     
14 13 / 0.01 x  70      x     
15 7 / 0.05 61 / 2.84  159  147 147   98  86 86  
16 x 7 / 0.30  171      164     
17 194 / 0.01 285 / 2.02  550 458  458 432 i  265 173  173 147 
18 142 / 0.06 211 / 0.48  427 220  220   216 9  9  
19 337 / 0.02 x  421 205  205   x x  x  
20 4 / 0.02 17 / 0.30      129 ii      112 
21 4 / 0.02 x    134 134     x  x  
22 51 / 0.06 x   198  198    x  x  
23 336 / 0.04 x    370 370     x x  
24 356 / 0.01 x    391 391     x x  
25 55 / 0.02 328 / 0.67    336 336     8 8  
26 x 9 / 0.20    252 252     243 243  
27 184 / 0.08 275 / 0.19   401  401    126  126  
28 5 / 0.05 x      6 ii      x 
29 680 / 0.01 x   667  667    x  x  
30 553 / 0.01 x   582  582    x  x  
31 721 / 0.01 x   272  272    x  x  
32 11 / 0.159 363 / 3.54  851 420  420   488 57  57  
33 169 / 0.14 218 / 0.33  586  491 491 8 iii  368  273 273 -210 
34 11 / 0.04 x  822  118 118   x  x x  
35 47 / 0.01 845 / 0.24      845 iv      0 
36 833 / 0.05 x      370 iii      x 
37 740 / 0.01 894 / 1.24   991  991    97  97  
38 1640 / 0.02 x      1633 iii      x 
39 x 3273 / 0.48  3477  3428 3428   204  155 155  
40 1164 / 0.04 x   1164  1164    x  x  
41 114 / 0.05 247 / 7.82   290  290    43  43  
42 467 / 0.01 551 / 0.92    234 234 234 iv    -317 -317 -317 
43 4111 / 0.01 x    3943 3943 3941 iv    x x x 
44 125 / 0.01 x    215 215     x x  
45 792 / 0.01 x   1011  1001    x  x  
46 178 / 0.04 x    178 178     x x  
47 x 547 / 0.35  925  542 542   378  -5 -5  
48 7/0.09 34 / 1.37    34 34     0 0  
49 230 / 0.03 321 / 0.21   334 334 334    13 13 13  
50 63 / 0.13 121 / 9.53  267 202 202 202   146 81 81 81  
51 8 / 0.05 x  66      x     
52 x 345 / 0.17   722  722    377  377  
53 x 8 / 0.37  38      30     
54 71 / 0.01 x  125      x     
55 15 / 0.04 x  276      x     
56 7 / 0.07 x      613 iii      x  
57 x 17 / 3.32  133      116     
58 140 / 0.01 x  263 127  127   x x  x  
59 180 / 0.01 271 / 1.23   587 281 281 317 v   316  10 46 
60 1485 / 0.01 x    1538 1538     x x  
61 288 / 0.05 x    309 309     x x  
62 9 / 0.02 100 / 0.23    259 259     159 159  
63 793 / 0.01 912 / 0.26      1255 vi      343 
*
 after treatment start 
i 
pancreatic cancer, 
ii
 colorectal cancer, 
iii 
lung cancer, 
iv
 HNSCC, 
v
 gastric cancer, 
vi
 esophageal cancer  
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Supplemental Figure 1 
 
Supplemental Figure 1: Genomic organization (introns, exons, transcripts, regulatory elements, CG 
content) of the SHOX2 and SEPT9 genes and regions targeted for methylation analyses. SEPT9 is 
located on chromosome 17:77,280,569-77,500,596 (forward strand) and has 47 transcripts. The 
qMSP and the Infinium bead cg12783819 used for methylation analyses target a region within a CpG 
island of a putative alternative promoter found in close proximity to the transcription start sites 
(Eponine, [1]) of transcript variants 008, 009, 030-035, and 062. SHOX2 is encoded on chromosome 
3:158,095,954-158,106,503 (reverse strand) and has 5 protein coding transcripts. The qMSP and the 
Infinium bead cg12993163 assess the methylation level at the putative transcription start site 
(Eponine) of transcript 201. All information was taken from Ensembl genome assembly GRCh38.p7 
(www.ensembl.org). 
 
Reference 
1. Down TA, Hubbard TJP. Computational detection and location of transcription start sites in 
mammalian genomic DNA. Genome Res 2002;12:458-61. 
Supplemental Results 1 
SEPT9-024 > protein coding
SEPT9-001 > protein coding
SEPT9-059 > nonsense mediated decay
SEPT9-016 > protein coding
SEPT9-036 > nonsense mediated decay
SEPT9-202 > protein coding
SEPT9-004 > protein coding
SEPT9-026 > processed transcript
SEPT9-201 > protein coding
SEPT9-006 > protein coding
SEPT9-038 > nonsense mediated decay
SEPT9-027 > protein coding
SEPT9-028 > protein coding
SEPT9-060 > protein coding
SEPT9-029 > processed transcript
SEPT9-008 > protein coding
SEPT9-030 > protein coding
SEPT9-031 > processed transcript
SEPT9-032 > processed transcript
SEPT9-033 > processed transcript
SEPT9-009 > protein coding
SEPT9-034 > protein coding
SEPT9-062 > protein coding
SEPT9-035 > processed transcript
SEPT9-010 > protein coding
SEPT9-011 > protein coding
SEPT9-040 > protein coding
SEPT9-054 > protein coding
SEPT9-042 > protein coding
SEPT9-043 > protein coding
SEPT9-012 > protein coding
SEPT9-045 > protein coding
SEPT9-014 > protein coding
SEPT9-061 > processed transcript
SEPT9-047 > protein coding
SEPT9-013 > protein coding
SEPT9-048 > protein coding
SEPT9-049 > protein coding
SEPT9-050 > protein coding
SEPT9-051 > protein coding
SEPT9-052 > protein coding
SEPT9-015 > protein coding
SEPT9-055 > protein coding
SEPT9-063 > protein coding
77.3Mb 77.4Mb 77.5Mb
cg12993163
< SHOX2-002 protein coding
< SHOX2-201 protein coding
< SHOX2-001 protein coding
< SHOX2-003 protein coding
< SHOX2-005 protein coding
158.096Mb 158.098Mb 158.100Mb 158.102Mb 158.104Mb 158.106Mb
cg12783819
qMSP
qMSP
 227.87 kb 
 12.07 kb  Reverse strand 
CpG Island
Promoter
Promoter Flank
CTCF Binding Site
Enhancer
Open Chromatin
Transcription Factor Binding Site
SEPT9
SHOX2
% CG
% CG
 Reverse strand 
Regulation Legend
Transcription Start Site (Eponine)
 33 
Supplemental Results 1 
 
SHOX2 and SEPT9 DNA methylation in tissues and matched plasma specimens  
Methylation levels of 527 HNSCC and 50 normal adjacent tissues from TCGA 
(http://cancergenome.nih.gov/.) were analyzed. The methylation data generated by the TCGA 
Research Network were created by means of the Infinium HumanMethylation450 BeadChip (Illumina, 
Inc., San Diego, CA, USA). HumanMethylation450 data of level 2 including background-corrected 
methylated (Intensity_M) and unmethylated (Intensity_U) summary intensities as extracted by the R 
package ‘methylumi’ were downloaded. The two beads cg12783819 and cg12993163, that hybridize 
to CpG-sites within the target region of the SEPT9 and SHOX2 qPCR assays (Supplemental Figure 
1), were evaluated. Methylation values for each bead were calculated by the formula 100% x 
Intensity_M / (Intensity_M + Intensity_U). SHOX2 and SEPT9 were found to be hypermethylated in 
tumor tissues compared to normal adjacent tissues (diagnostic accuracy: AUCSEPT9=0.89, 95%CI 
[0.85–0.94], AUCSHOX2=0.98, 95%CI [0.97-0.99], P<0.001; Supplemental Figure 2). While mean 
methylation levels of both genes in HNSCC tissue were similar (SEPT9: 52.4% vs. SHOX2: 49.9%), 
twenty-one out of 527 (4%) tumors showed only low level SEPT9 methylation <5%. However, these 21 
tumor tissues had a mean average SHOX2 methylation of 51.7%. In contrast, only 3/527 (0.6%) of 
HNSCC tissues had a SHOX2 methylation <5%. All these three tumors were SEPT9 hypermethylated. 
Thus, both biomarkers analyzed as a biomarker panel added independent information. Interestingly, 
mean SEPT9 methylation in normal adjacent tissues (NAT) was higher (17.7%) compared to mean 
SHOX2 methylation (12.4%). However, Supplemental Figure 2 illustrates that the SHOX2 methylation 
in NAT was homogeneously distributed around the mean, while SEPT9 methylation was characterized 
by a higher methylation variance within NAT. Four out of 50 (8%) NATs showed a SEPT9 methylation 
higher than the mean SEPT9 methylation in HNSCC. On the other hand, 22/50 (44%) NATs showed 
only low level methylation <5%, while 41/50 (82%) NATs exhibited SHOX2 methylation >5%. Hence, 
SHOX2 background methylation in plasma can be expected in a higher number of individuals without 
HNSCC compared to SEPT9. Interestingly, SHOX2 and SEPT9 methylation in HNSCC from smokers 
correlated significantly with the number of pack years (SHOX2: Spearman’s ρ = 0.15, P = 0.012; 
SEPT9: ρ = 0.17, P = 0.003).  
The feasibility to detect SEPT9 and SHOX2 hypermethylated ccfDNA in blood plasma from HNSCC 
patients was tested in a small patient group. Matched tumor samples and pre-therapeutic blood 
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samples from 55 patients were analyzed. For DNA methylation analyses of formalin-fixed and paraffin-
embedded tumor tissues, bisulfite DNA was prepared using the innuCONVERT All-In-One Bisulfite Kit 
(Analytik Jena, Jena, Germany) according to the manufacturer’s protocol. Mean methylation in these 
55 HNSCC tissues was 51.1% (SEPT9) and 71.88% (SHOX2), respectively. Mean methylation in the 
55 corresponding plasma samples was 2.08% (SEPT9) and 3.87% (SHOX2), respectively. SHOX2 
methylation in plasma correlated significantly with tissue methylation levels (ρ = 0.36, P = 0.007), while 
SEPT9 only showed a trend towards higher methylation in plasma from patients with SEPT9 
hypermethylated tumors (ρ = 0.25, P = 0.067). As already found in the TCGA HNSCC cohort, a higher 
number of tumors (18/55, 33%) showed only low level (< 5%) SEPT9 methylation in tissue, while only 
1/55 (2%) tumors exhibited SHOX2 methylation < 5%. Mean SHOX2 methylation in the 18 HNSCC 
tissues with SEPT9 methylation <5% was 94.6% and mean SHOX2 plasma methylation was 6.2% 
with 12/18 (67%) plasma samples showing SHOX2 methylation >1%, thus confirming the additive 
value of both biomarkers.  
 
 
Supplemental Figure 2: SHOX2 and SEPT9 DNA methylation levels in HNSCC tumor (n=527) and 
normal adjacent tissues (n=50). Each rhombus reflects one sample measurement, and mean values 
(black bars) are given. P-values refer to Wilcoxon-Mann-Whitney test. ROC analysis and the resulting 
AUCs are shown. The results shown here are based upon data generated by the TCGA Research 
Network: http://cancergenome.nih.gov/. 
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Supplemental Results 2 
 
SHOX2 and SEPT9 DNA methylation in plasma for disease monitoring: selected cases  
Monitoring results of eight exemplary patients are described in Supplemental Figure 3. A 61-year old 
man (patient 11) diagnosed with a recurrent carcinoma of the larynx (T4, N2, G2, V1, L1, R0, M0) was 
treated with surgery and adjuvant radio-chemotherapy. Before treatment, 0.41% methylation were 
detected in plasma. On day eleven after surgery, blood methylation was below the cut-off (0.08%) and 
remained negative when measured on day 120 and 384 after surgery. Strongly positive results were 
first recorded on day 475 (1.19%) and 566 (4.36%), respectively. However, pulmonary metastases 
were already diagnosed on day 126 via computer tomography (CT). In this case, the diagnosis of 
systemic progression via CT imaging was superior to methylation testing in blood.  
Blood from a 72-year old man (patient 5) was negative 6 days after surgical resection of a recurrent 
carcinoma of the oropharynx (T4, N0, G2, L1, V0, R0, M0). A blood sample prior to surgery was not 
available. Methylation testing was negative (0.01%) on day 6 after surgery. The first strongly positive 
test result (1.22%) was obtained on day 62. Adjuvant radio-chemotherapy started on day 110. The 
patient died 238 days after surgery without diagnosis of a local or systemic progression. However, all 
five blood test between day 6 and 181 were strongly positive, indicating that the patient in fact died 
from an occult tumor progression. 
Patient 17, a 60-year old man, was diagnosed with a T3, Nx, G2, V0, L0, R0, M0 squamous cell 
carcinoma on the tip of his nose and was surgically treated. The blood testing was slightly positive 
before surgery (0.18%). Adjuvant radiotherapy started on day 59. A second blood sample was 
analyzed on day 194 with negative results (0.01%). The next blood samples on days 285 and 313 
were strongly positive. Eventually, a second primary cancer (pancreatic ductal adenocarcinoma) was 
diagnosed on day 432, one hundred and forty-seven days after the first positive blood sample. 
However, the pancreatic cancer was diagnosed at an advanced (unresectable) stage, and the patient 
died on day 550. While an earlier diagnosis of the second cancer based on methylation testing would 
have been possible, it is not clear whether the patient would have benefitted due to the adverse 
prognosis of the second cancer and the lack of therapeutic options.   
A 57-year old man (patient 50) had a methylation positive (0.93%) blood test prior to a definitive radio-
chemotherapy of a T3, N2, G2, M0 carcinoma of the hypopharynx. In the course of radio-
chemotherapy, methylation levels in the blood decreased to 0.13% on day 63. A dramatic recurrence 
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of methylated tumor ccfDNA was detected on day 121 (9.53%), 140 (14.65%), and 217 (54.93%). The 
patient died 267 days after the initiation of the therapy. Multiple distant metastases (pulmonary, 
skeletal, hepatic) were diagnosed on day 219, ninety-eight days after the first strongly positive blood 
result.  
Methylation levels in the blood from patient 27 (male, 69 years old), who suffered from a surgically 
resected T2, N2, G2, L0, V0, R0, M0 carcinoma of the larynx, was strongly positive (0.85%) before 
treatment started. Negative blood test results were obtained on day 5 and 184 after surgery. On day 
275, a first moderately positive (0.19%) test result was observed. Distant (hepatic) metastases were 
diagnosed on day 401, one hundred and twenty-six days after the first positive test result.  
Patient 4 was a 69-year old male with a surgically resected T1, N2, G3, L0, V0, R0, M0 SCC of the 
oral cavity. Strongly positive methylation levels (3.55%) were found before treatment but decreased 
below the cut-off on day 13 after surgery. A fulminant recurrent methylation level (10.89%) was 
detected on day 61 after surgery. Twenty-two days later, a loco-regional relapse was diagnosed. 
The 61 years old male patient 63 was a heavy smoker (75 pack years) and former alcoholic, who 
received surgery and adjuvant radio-chemotherapy because of a T3, N1, G3, L1, V1, R0, M0 laryngeal 
SCC. No methylated DNA was detected in the blood on day 793 after surgery. Slightly elevated 
methylation levels above the cut-off were measured on days 912 and 1087 before strong positive test 
results were obtained on day 1178 and 1255. A second cancer (N1, M0, oesophageal squamous cell 
carcinoma) was diagnosed on day 1255, a total of 343 days after the first positive blood test result. 
Patient 7 (70 years old, male) showed strongly positive methylation levels prior to and after surgical 
resection of a T4, N2, G3, L1, V0, R1, M0 carcinoma of the hypopharynx. A lymph node metastasis 
was diagnosed on day 29, and the patient received a palliative cisplatin/docetaxel-based 
chemotherapy starting on day 41. However, blood methylation levels remained strongly positive on 
day 64, 99, and 134. Accordingly, progressive disease was diagnosed on day 74. 
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Supplemental Figure 3: Eight selected cases are depicted in detail. Methylation levels (SHOX2 and 
SEPT9 methylation mean averaged) below 0.01% were set to 0.01% in order to allow for a logarithmic 
illustration.  
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Supplemental Protocol 1 
 
Plasma Preparation  
Blood was collected using S-Monovette® (9 ml) K3 EDTA collection tubes (Sarstedt AG & Co., 
Nümbrecht, Germany). The blood was centrifuged for 6 min at 1.350 g, and the plasma was 
transferred to a new tube. A second centrifugation step was performed for 6 min at 3,000 g, and 3 ml 
plasma were transferred to a new 15 ml centrifugation tube. Plasma was prepared within 2 hours after 
sampling and immediately stored at -20°C for up to 6 months.  
 
Bisulfite Conversion 
3 ml Silane lysis/binding buffer (viral NA, Thermo Fisher Scientific, Waltham, MA, USA) were added to 
3 ml plasma and incubated for 10 min at room temperature. 65 µl Dynabeads® SILANE (Thermo 
Fisher Scientific) and 2.2 ml ethanol (absolute, molecular biology grade) were added, and the mixture 
was incubated 45 min at 20 rpm in a rotator. The reaction tube was transferred to a DynaMag™-15 
magnet (Thermo Fisher Scientific), and the supernatant was discarded. The beads were washed with 
wash buffer I (50% [v/v] Silane lysis/binding buffer (viral NA), 50% [v/v] ethanol) and eluted with 100 µl 
water. A total of 150 µl ammonium bisulfite (65%, pH 5.3, TIB Chemicals AG, Mannheim, Germany) 
and 25 µl denaturation buffer (70 mg/ml trolox [(±)-6-hydroxy-2,5,7,8-tetramethylchromane-2-
carboxylic acid] in THFA [tetrahydrofurfuryl alcohol]) were added to the eluted DNA, and the reaction 
mixture was incubated for 45 min at 85°C. After conversion reaction, 15 µl Dynabeads® SILANE and 1 
ml wash buffer I were added and incubated for 45 min at 1,000 rpm and 23°C in a thermomixer. The 
tube was transferred to a DynaMag™-2 magnet (Thermo Fisher Scientific), and the bound DNA was 
washed once with wash buffer I and three times with wash buffer II (15% [v/v] water and 85% [v/v] 
ethanol, absolute). Finally, the bisulfite converted DNA was eluted with 65 µl elution buffer (10 mM 
Tris-HCl, pH 8.0).  
 
 
